InvestorsHub Logo
Followers 4
Posts 1191
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Thursday, 02/04/2021 10:50:12 PM

Thursday, February 04, 2021 10:50:12 PM

Post# of 932
Compared to ACTolog® (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which
autologous T cell products are directed against multiple novel defined peptide-HLA (pHLA) cancer
targets identified by the target discovery platform XPRESIDENT

ACTolog® target warehouse: COL6A3 exon 6, PRAME, MAGEA1, MAGEA4, MAGEA8, CTAG1A/NYESO-1, MXRA5, MMP1. Targeting the novel tumor stroma target COL6A3 exon 6 is intended to disrupt the tumor microenvironment